Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy

Nephrology Dialysis Transplantation

Volumn 26, Issue 9, 2011, Pages 2871-2877

  Aaltonen, Sari ^a   Honkanen, Eero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Immunosuppressive treatment; membranous nephropathy; survival

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CATARACT; CELLULITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SIDE EFFECT; SURVIVAL RATE; TOXIC HEPATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

CYCLOPHOSPHAMIDE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053206740     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq841     Document Type: Article

References (39)

1. Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
2. Honkanen E. Survival in idiopathic membranous glomerulonephritis. Clin Nephrol 1986; 25: 122-128 (Pubitemid 16164547)
3. Honkanen E, Tornroth T, Gronhagen-Riska C et al. Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted? Clin Nephrol 1994; 41: 127-134 (Pubitemid 24085374)
4. Cattran DC, Pei Y, Greenwood CM et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51: 901-907 (Pubitemid 27157980)
5. Ponticelli C, Passerini P, Altieri P et al. Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 1992; 7 (Suppl 1): 85-90 (Pubitemid 23016773)
6. Troyanov S, Wall CA, Miller JA et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66: 1199-1205 (Pubitemid 39121029)
7. Donadio JV Jr, Torres VE, Velosa JA et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988; 33: 708-715 (Pubitemid 18083120)
8. Erwin DT, Donadio JV Jr, Holley KE. The clinical course of idiopathic membranous nephropathy. Mayo Clin Proc 1973; 48: 697-712
9. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-89 (Pubitemid 23188821)
10. Honkanen E, Tornroth T, Gronhagen-Riska C. Natural history, clinical course and morphological evolution of membranous nephropathy. Nephrol Dial Transplant 1992; 7 (Suppl 1): 35-41 (Pubitemid 23016765)
11. Abe S, Amagasaki Y, Konishi K et al. Idiopathic membranous glomerulonephritis: aspects of geographical differences. J Clin Pathol 1986; 39: 1193-1198 (Pubitemid 17187735)
12. Glassock RJ. Corticosteroid therapy is beneficial in adults with idiopathic membranous glomerulopathy. Am J Kidney Dis 1982; 1: 376-385 (Pubitemid 12017054)
13. Tang S, Chan TM, Cheng IK et al. Clinical features and treatment outcome of idiopathic membranous nephropathy in Chinese patients. QJM 1999; 92: 401-406 (Pubitemid 29346885)
14. du Buf-Vereijken PW, Feith GW, Hollander D et al. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort. QJM 2004; 97: 353-360 (Pubitemid 38807415)
15. Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J Am Soc Nephrol 1995; 5: 1553-1558
16. Perna A, Schieppati A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004; 44: 385-401 (Pubitemid 39164615)
17. Ponticelli C, Zucchelli P, Imbasciati E et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984; 310: 946-950 (Pubitemid 14173232)
18. Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995; 47: 1130-1135
19. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960-966
20. Rosen S, Tornroth T, Bernard BB. Membranous glomerulonephritis. In: Tisher CC, Brenner BM eds. Renal Pathology. 2nd edn. Philadelphia, PA: J.B. Lippincott Company, 1994; p. 258
21. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254 (Pubitemid 46768608)
22. Cattran DC. Treatment of idiopathic membranous nephropathy. 2009. www.UpToDate.com-Website
23. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N Engl J Med 1979; 301: 1301-1306
24. Cameron JS, Healy MJ, Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med 1990; 74: 133-156 (Pubitemid 20059786)
25. Cattran DC, Delmore T, Roscoe J et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 1989; 320: 210-215 (Pubitemid 19034146)
26. Chan TM, Lin AW, Tang SC et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007; 12: 576-581 (Pubitemid 350059122)
27. Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450 (Pubitemid 28122870)
28. Ponticelli C, Zucchelli P, Passerini P et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 1992; 327: 599-603
29. Alexopoulos E, Sakellariou G, Memmos D et al. Cyclophosphamide provides no additional benefit to steroid therapy in the treatment of idiopathic membranous nephropathy. Am J Kidney Dis 1993; 21: 497-503 (Pubitemid 23160510)
30. Ponticelli C, Zucchelli P, Passerini P et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320: 8-13 (Pubitemid 19033056)
31. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604
32. Warwick GL, Geddes CG, Boulton-Jones JM. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med 1994; 87: 223-229 (Pubitemid 24113249)
33. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1490 (Pubitemid 32281239)
34. Branten AJ, du Buf-Vereijken PW, Vervloet M et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50: 248-256 (Pubitemid 47095081)
35. Ponticelli C, Passerini P, Salvadori M et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47: 233-240 (Pubitemid 43121326)
36. Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73: 117-125 (Pubitemid 350273646)
37. Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 2003; 14: 1851-1857 (Pubitemid 36750480)
38. Praga M, Barrio V, Juarez GF. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007; 71: 924-930 (Pubitemid 46663803)
39. Shiiki H, Saito T, Nishitani Y et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 2004; 65: 1400-1407 (Pubitemid 38406980)